Search results
Results from the Tech24 Deals Content Network
August 8, 2024 at 11:52 AM. Shares of Viatris (NASDAQ: VTRS) were jumping 6% higher as of 11:18 a.m. ET on Thursday after rising as much as 12.4% earlier in the day. The solid gain came after the ...
Viatris (VTRS) closed the most recent trading day at $15.17, moving -0.98% from the previous trading session.
Viatris (VTRS) delivered earnings and revenue surprises of 8.64% and 0.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn , a legacy division of Pfizer , on November 16, 2020.
Viatris also reaffirmed its full-revenue revenue forecast to the range of $15.5 billion to $16 billion, compared to analysts' estimates of $15.60 billion. Viatris beats second-quarter revenue ...
Viatris (VTRS) delivered earnings and revenue surprises of 14.81% and 0.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Viatris (VTRS) closed the most recent trading day at $10.99, moving -1.7% from the previous trading session.
Viatris' (VTRS) subsidiary is the first to receive approval from the FDA to market a generic version of AbbVie's Restasis for the treatment of dry eye disease.